HAWK/HARRIER phase 3 results show non-inferiority of brolucizumab for BCVA gains in neovascular AMD

Arshad Khanani
VANCOUVER, British Columbia — Brolucizumab achieved its primary endpoint of best corrected visual acuity noninferiority at week 48 to aflibercept in the results of two phase 3 studies of the treatment in neovascular age-related macular degeneration patients, according to a speaker here.
“Brolucizumab achieved its primary endpoint of noninferiority of BCVA change vs. aflibercept at week 48. Patients treated with brolucizumab achieved superior reductions in CST compared to aflibercept. Fewer patients treated with brolucizumab had sub-retinal fluid, inter-retinal fluid,

Full Story →